JP Morgan Chase’s Fennec Pharmaceuticals FENC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $134K | Buy |
12,143
+284
| +2% | +$2.32K | ﹤0.01% | 5832 |
|
|
2026
Q1 | $68.4K | Buy |
11,859
+2,088
| +21% | +$16.1K | ﹤0.01% | 6037 |
|
|
2025
Q4 | $75.2K | Sell |
9,771
-55
| -0.6% | -$452 | ﹤0.01% | 6041 |
|
|
2025
Q3 | $92K | Sell |
9,826
-1,251
| -11% | -$10.8K | ﹤0.01% | 5948 |
|
|
2025
Q2 | $91.9K | Sell |
11,077
-644
| -5% | -$4.41K | ﹤0.01% | 5643 |
|
|
2025
Q1 | $71.4K | Buy |
11,721
+952
| +9% | +$6.11K | ﹤0.01% | 5731 |
|
|
2024
Q4 | $68.1K | Buy |
10,769
+264
| +3% | +$1.35K | ﹤0.01% | 5900 |
|
|
2024
Q3 | $52.5K | Buy |
10,505
+191
| +2% | +$1.1K | ﹤0.01% | 5970 |
|
|
2024
Q2 | $63K | Buy |
10,314
+491
| +5% | +$4.08K | ﹤0.01% | 5759 |
|
|
2024
Q1 | $109K | Sell |
9,823
-3,276
| -25% | -$32.9K | ﹤0.01% | 5634 |
|
|
2023
Q4 | $147K | Buy |
13,099
+1,266
| +11% | +$10.5K | ﹤0.01% | 5552 |
|
|
2023
Q3 | $88.9K | Sell |
11,833
-2,699
| -19% | -$22K | ﹤0.01% | 5552 |
|
|
2023
Q2 | $128K | Buy |
14,532
+14,462
| +20,660% | +$120K | ﹤0.01% | 5345 |
|
|
2023
Q1 | $1K | Hold |
70
| – | – | ﹤0.01% | 6516 |
|
|
2022
Q4 | $1K | Hold |
70
| – | – | ﹤0.01% | 6404 |
|
|
2022
Q3 | $1K | Sell |
70
-7,665
| -99% | -$52.6K | ﹤0.01% | 6320 |
|
|
2022
Q2 | $69K | Sell |
7,735
-8,631
| -53% | -$50.1K | ﹤0.01% | 5557 |
|
|
2022
Q1 | $91K | Buy |
16,366
+16,296
| +23,280% | +$82.1K | ﹤0.01% | 5549 |
|
|
2021
Q4 | $0 | Buy |
+70
| New | +$521 | ﹤0.01% | 6740 |
|
|
2021
Q3 | – | Sell |
-20,021
| Closed | -$146K | – | 6570 |
|
|
2021
Q2 | $146K | Sell |
20,021
-2,893
| -13% | -$19.3K | ﹤0.01% | 5390 |
|
|
2021
Q1 | $142K | Buy |
22,914
+13,244
| +137% | +$99.7K | ﹤0.01% | 5284 |
|
|
2020
Q4 | $72K | Buy |
9,670
+1,699
| +21% | +$12.9K | ﹤0.01% | 5069 |
|
|
2020
Q3 | $48K | Buy |
7,971
+706
| +10% | +$4.98K | ﹤0.01% | 4940 |
|
|
2020
Q2 | $61K | Buy |
+7,265
| New | +$54K | ﹤0.01% | 4759 |
|
|
2019
Q4 | – | Sell |
-110
| Closed | -$1K | – | 5692 |
|
|
2019
Q3 | $1K | Buy |
+110
| New | +$485 | ﹤0.01% | 5649 |
|
|
2019
Q2 | – | Sell |
-2,831
| Closed | -$14K | – | 5822 |
|
|
2019
Q1 | $14K | Sell |
2,831
-802
| -22% | -$5.27K | ﹤0.01% | 5474 |
|
|
2018
Q4 | $23K | Buy |
3,633
+946
| +35% | +$6.61K | ﹤0.01% | 5293 |
|
|
2018
Q3 | $22K | Sell |
2,687
-35,449
| -93% | -$329K | ﹤0.01% | 5404 |
|
|
2018
Q2 | $398K | Buy |
+38,136
| New | +$452K | ﹤0.01% | 4277 |
|
Other funds holding FENC
RA
ACM
SCM
AIC
PCA
JP Morgan Chase's FENC Position: Q2 2026 in Review
JP Morgan Chase increased its Fennec Pharmaceuticals (FENC) stake by 2.4% in Q2 2026, buying an estimated $2.32K and bringing the position to 12,143 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #5832.
JP Morgan Chase first reported a position in FENC in Q2 2018 and has held it in 29 quarters since. The position peaked at $398K in Q2 2018. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.
- JP Morgan Chase held 12,143 shares of Fennec Pharmaceuticals worth $134K as of Q2 2026.
- JP Morgan Chase bought 284 Fennec Pharmaceuticals shares in Q2 2026, an estimated $2.32K.
- Fennec Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5832 holding.
- JP Morgan Chase first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
- JP Morgan Chase's Fennec Pharmaceuticals position peaked at $398K in Q2 2018.
- 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.